Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$142.24 USD
-0.80 (-0.56%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $142.35 +0.11 (0.08%) 6:34 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 561 - 580 ( 669 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patient Dosing and NDA Submission Remains on Track
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
If Exon Skipping Works Then Why the Deterioration?
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clarification on the Termination of the Company''s CSO
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Uncharted Waters and Single Data Point Adds Noise to the 144 Weeks Data
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Fails to Meet High Expectations. Price Target Lowered to $34
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Setting Expectations Ahead of the 144 Week Data Event
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Confirmatory Study Dosing and NDA Submission Timelines Remain on Track
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.